Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy | Journal of Clinical Pathology

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via ACP

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Citation Tools

Original article

Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Chen Y, Tsao S, Tsai H, et al

Serine protease inhibitor Kazal type 1 (SPINK1) as a prognostic marker in stage IV colon cancer patients receiving cetuximab based targeted therapy

Journal of Clinical Pathology 2016;69:974-978.